**1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine** is a chemical compound that serves as a **potent inhibitor of the enzyme carbonic anhydrase (CA)**.
**Carbonic anhydrases** are a family of enzymes that catalyze the reversible hydration of carbon dioxide to bicarbonate and protons. This reaction plays a critical role in various physiological processes, including:
* **Respiratory gas transport:** CA facilitates the conversion of CO2 to bicarbonate in red blood cells, allowing for efficient transport of CO2 from tissues to the lungs.
* **Acid-base balance:** CA helps maintain the pH of blood and other bodily fluids.
* **Bone formation:** CA is involved in the formation of hydroxyapatite, the mineral component of bones.
**Importance for Research:**
* **Drug discovery:** 1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine, along with other CA inhibitors, has potential therapeutic applications in various diseases, including:
* **Glaucoma:** CA inhibitors are used to reduce intraocular pressure by inhibiting CA in the eye.
* **Epilepsy:** Some CA inhibitors have shown anticonvulsant activity.
* **Cancer:** CA inhibitors have been investigated as potential anticancer agents.
* **Obesity:** CA inhibitors may have a role in regulating appetite and body weight.
* **Chemical biology:** 1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine can be used as a tool to study the role of CA in various biological processes.
* **Materials science:** CA inhibitors have been explored for their potential applications in materials science, such as in the development of sensors and catalysts.
**Mechanism of Action:**
1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine inhibits CA by binding to the active site of the enzyme, preventing the hydration of carbon dioxide. The nitro group on the phenyl ring enhances the inhibitory activity of the compound.
**Conclusion:**
1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine is a potent CA inhibitor with significant research interest due to its potential applications in drug discovery, chemical biology, and materials science. Its ability to inhibit CA activity has made it a valuable tool for investigating the role of this enzyme in various physiological and pathological processes.
ID Source | ID |
---|---|
PubMed CID | 3025945 |
CHEMBL ID | 1407805 |
CHEBI ID | 93634 |
Synonym |
---|
1-((4-nitrophenyl)sulfonyl)-1h-benzimidazol-2-amine |
MLS-0425617.0001 , |
MLS002639483 |
smr001548927 |
1-(4-nitrophenyl)sulfonylbenzimidazol-2-amine |
MLS-0425617.0002 |
193696-63-8 |
CHEMBL1407805 |
bdbm62306 |
cid_3025945 |
1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine |
(1-nosylbenzimidazol-2-yl)amine |
DTXSID40172977 |
CHEBI:93634 |
Q27165328 |
Class | Description |
---|---|
sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
TDP1 protein | Homo sapiens (human) | Potency | 24.8446 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Smad3 | Homo sapiens (human) | Potency | 12.5893 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 5.0119 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 89.1251 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
interleukin-8 isoform 1 precursor | Homo sapiens (human) | IC50 (µMol) | 5.0000 | 0.5507 | 4.3977 | 18.7700 | AID2245; AID2250; AID2260 |
tumor necrosis factor | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0793 | 5.8098 | 14.7275 | AID2337 |
nucleotide-binding oligomerization domain-containing protein 1 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 22.2500 | 0.0431 | 3.3619 | 18.4900 | AID2255; AID2261; AID2264; AID2333 |
nucleotide-binding oligomerization domain-containing protein 2 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 1.1460 | 7.1372 | 19.7000 | AID2334 |
Nucleotide-binding oligomerization domain-containing protein 2 | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0370 | 4.3307 | 7.9433 | AID655844 |
Nucleotide-binding oligomerization domain-containing protein 1 | Homo sapiens (human) | IC50 (µMol) | 14.0000 | 0.0900 | 0.9691 | 2.7000 | AID655843 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID655845 | Inhibition of TNFalpha-induced NFkappaB activation in HEK293T cells after 14 hrs by luciferase reporter gene assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10 | Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
AID655846 | Cytotoxicity against HEK293T cells at 20 uM by alamar blue assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10 | Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
AID655844 | Inhibition of NOD-2 mediated NFkappaB activation in HEK293T cells assessed as inhibition of MDP-induced luciferase activity after 14 hrs by reporter gene assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10 | Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
AID655843 | Inhibition of NOD-1 mediated NFkappaB activation in HEK293T cells assessed as inhibition of gamma-tri-DAP-induced luciferase activity after 14 hrs by reporter gene assay | 2011 | ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10 | Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |